438 related articles for article (PubMed ID: 20521635)
1. Use of antigenic cartography in vaccine seed strain selection.
Fouchier RA; Smith DJ
Avian Dis; 2010 Mar; 54(1 Suppl):220-3. PubMed ID: 20521635
[TBL] [Abstract][Full Text] [Related]
2. Comparative efficacy of North American and antigenically matched reverse genetics derived H5N9 DIVA marker vaccines against highly pathogenic Asian H5N1 avian influenza viruses in chickens.
Jadhao SJ; Lee CW; Sylte M; Suarez DL
Vaccine; 2009 Oct; 27(44):6247-60. PubMed ID: 19686695
[TBL] [Abstract][Full Text] [Related]
3. Cross-Protection by Inactivated H5 Prepandemic Vaccine Seed Strains against Diverse Goose/Guangdong Lineage H5N1 Highly Pathogenic Avian Influenza Viruses.
Criado MF; Sá E Silva M; Lee DH; Salge CAL; Spackman E; Donis R; Wan XF; Swayne DE
J Virol; 2020 Nov; 94(24):. PubMed ID: 32999029
[TBL] [Abstract][Full Text] [Related]
4. Experimental challenge of chicken vaccinated with commercially available H5 vaccines reveals loss of protection to some highly pathogenic avian influenza H5N1 strains circulating in Hong Kong/China.
Connie Leung YH; Luk G; Sia SF; Wu YO; Ho CK; Chow KC; Tang SC; Guan Y; Malik Peiris JS
Vaccine; 2013 Aug; 31(35):3536-42. PubMed ID: 23791547
[TBL] [Abstract][Full Text] [Related]
5. The Molecular Determinants of Antibody Recognition and Antigenic Drift in the H3 Hemagglutinin of Swine Influenza A Virus.
Abente EJ; Santos J; Lewis NS; Gauger PC; Stratton J; Skepner E; Anderson TK; Rajao DS; Perez DR; Vincent AL
J Virol; 2016 Sep; 90(18):8266-80. PubMed ID: 27384658
[TBL] [Abstract][Full Text] [Related]
6. A proof-of-principle study to identify suitable vaccine seed candidates to combat introductions of Eurasian lineage H5 and H7 subtype avian influenza viruses.
Beato MS; Monne I; Mancin M; Bertoli E; Capua I
Avian Pathol; 2010 Oct; 39(5):375-82. PubMed ID: 20954014
[TBL] [Abstract][Full Text] [Related]
7. Genetic versus antigenic differences among highly pathogenic H5N1 avian influenza A viruses: Consequences for vaccine strain selection.
Peeters B; Reemers S; Dortmans J; de Vries E; de Jong M; van de Zande S; Rottier PJM; de Haan CAM
Virology; 2017 Mar; 503():83-93. PubMed ID: 28135661
[TBL] [Abstract][Full Text] [Related]
8. Evolution and Antigenic Advancement of N2 Neuraminidase of Swine Influenza A Viruses Circulating in the United States following Two Separate Introductions from Human Seasonal Viruses.
Kaplan BS; Anderson TK; Chang J; Santos J; Perez D; Lewis N; Vincent AL
J Virol; 2021 Sep; 95(20):e0063221. PubMed ID: 34379513
[TBL] [Abstract][Full Text] [Related]
9. Antigenic analysis of H5N1 highly pathogenic avian influenza viruses circulating in Egypt (2006-2012).
Ibrahim M; Eladl AH; Sultan HA; Arafa AS; Abdel Razik AG; Abd El Rahman S; El-Azm KI; Saif YM; Lee CW
Vet Microbiol; 2013 Dec; 167(3-4):651-61. PubMed ID: 24139721
[TBL] [Abstract][Full Text] [Related]
10. Monovalent H5 vaccine based on epitope-chimeric HA provides broad cross-clade protection against variant H5N1 viruses in mice.
He F; Prabakaran M; Rajesh Kumar S; Tan Y; Kwang J
Antiviral Res; 2014 May; 105():143-51. PubMed ID: 24637255
[TBL] [Abstract][Full Text] [Related]
11. Amino acid substitutions in antigenic region B of hemagglutinin play a critical role in the antigenic drift of subclade 2.3.4.4 highly pathogenic H5NX influenza viruses.
Li J; Gu M; Liu K; Gao R; Sun W; Liu D; Jiang K; Zhong L; Wang X; Hu J; Hu S; Liu X; Shi W; Ren H; Peng D; Jiao X; Liu X
Transbound Emerg Dis; 2020 Jan; 67(1):263-275. PubMed ID: 31484213
[TBL] [Abstract][Full Text] [Related]
12. Protective efficacy of an inactivated chimeric H5 avian influenza vaccine against H5 highly pathogenic avian influenza virus clades 2.3.4.4 and 2.3.2.1.
Li J; Hou G; Wang Y; Wang S; Cheng S; Peng C; Jiang W
J Gen Virol; 2018 Dec; 99(12):1600-1607. PubMed ID: 30358528
[TBL] [Abstract][Full Text] [Related]
13. Characterization of co-circulating swine influenza A viruses in North America and the identification of a novel H1 genetic clade with antigenic significance.
Anderson TK; Campbell BA; Nelson MI; Lewis NS; Janas-Martindale A; Killian ML; Vincent AL
Virus Res; 2015 Apr; 201():24-31. PubMed ID: 25701742
[TBL] [Abstract][Full Text] [Related]
14. Development of broadly reactive H5N1 vaccine against different Egyptian H5N1 viruses.
Ibrahim M; Sultan HA; Razik AG; Kang KI; Arafa AS; Shehata AA; Saif YM; Lee CW
Vaccine; 2015 May; 33(23):2670-7. PubMed ID: 25910922
[TBL] [Abstract][Full Text] [Related]
15. Recombinant influenza A virus vaccines for the pathogenic human A/Hong Kong/97 (H5N1) viruses.
Li S; Liu C; Klimov A; Subbarao K; Perdue ML; Mo D; Ji Y; Woods L; Hietala S; Bryant M
J Infect Dis; 1999 May; 179(5):1132-8. PubMed ID: 10191214
[TBL] [Abstract][Full Text] [Related]
16. Protection of mice and poultry from lethal H5N1 avian influenza virus through adenovirus-based immunization.
Gao W; Soloff AC; Lu X; Montecalvo A; Nguyen DC; Matsuoka Y; Robbins PD; Swayne DE; Donis RO; Katz JM; Barratt-Boyes SM; Gambotto A
J Virol; 2006 Feb; 80(4):1959-64. PubMed ID: 16439551
[TBL] [Abstract][Full Text] [Related]
17. Substitutions near the hemagglutinin receptor-binding site determine the antigenic evolution of influenza A H3N2 viruses in U.S. swine.
Lewis NS; Anderson TK; Kitikoon P; Skepner E; Burke DF; Vincent AL
J Virol; 2014 May; 88(9):4752-63. PubMed ID: 24522915
[TBL] [Abstract][Full Text] [Related]
18. Antigenic and molecular heterogeneity in recent swine influenza A(H1N1) virus isolates with possible implications for vaccination policy.
de Jong JC; Heinen PP; Loeffen WL; van Nieuwstadt AP; Claas EC; Bestebroer TM; Bijlsma K; Verweij C; Osterhaus AD; Rimmelzwaan GF; Fouchier RA; Kimman TG
Vaccine; 2001 Aug; 19(31):4452-64. PubMed ID: 11483271
[TBL] [Abstract][Full Text] [Related]
19. New DIVA vaccine for the protection of poultry against H5 highly pathogenic avian influenza viruses irrespective of the N-subtype.
Peeters B; de Boer SM; Tjeerdsma G; Moormann R; Koch G
Vaccine; 2012 Nov; 30(49):7078-83. PubMed ID: 23036502
[TBL] [Abstract][Full Text] [Related]
20. Further evidence of antigenic drift and protective efficacy afforded by a recombinant HVT-H5 vaccine against challenge with two antigenically divergent Egyptian clade 2.2.1 HPAI H5N1 strains.
Rauw F; Palya V; Van Borm S; Welby S; Tatar-Kis T; Gardin Y; Dorsey KM; Aly MM; Hassan MK; Soliman MA; Lambrecht B; van den Berg T
Vaccine; 2011 Mar; 29(14):2590-600. PubMed ID: 21292007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
